Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02988986
Title TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast Cancer
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Millennium Pharmaceuticals, Inc.
Indications

estrogen-receptor positive breast cancer

Therapies

Sapanisertib + Tamoxifen

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.